Press Releases

MGEN $5.75 $ - 0.03 (0.52%)

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
8/7/2018
4:05 PM ET
Earnings Release

miRagen Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

8/7/2018

Cobomarsen expansion indication data released; first observations from the ongoing Phase 1 clinical trial on safety and efficacy of cobomarsen in ATLL patients, additional data expected by year endNew...

 Continue Reading
8/6/2018
7:00 AM ET
Press Release

miRagen Therapeutics and The Leukemia & Lymphoma Society® Enter Into an Agreement to Facilitate the Development of Cobomarsen in Cutaneous T-Cell Lymphoma

8/6/2018

BOULDER, Colo. and RYE BROOK, N.Y., Aug. 06, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development o...

 Continue Reading
7/31/2018
7:00 AM ET
Press Release

miRagen Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference

7/31/2018

BOULDER, Colo., July 31, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...

 Continue Reading
7/25/2018
7:00 AM ET
Press Release

miRagen Therapeutics to Report Second Quarter 2018 Financial Results and Host Conference Call on August 7, 2018

7/25/2018

BOULDER, Colo., July 25, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...

 Continue Reading
7/10/2018
7:00 AM ET
Press Release

miRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201

7/10/2018

BOULDER, Colo., July 10, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therap...

 Continue Reading
Displaying 1 to 5 (of 60 releases)